ORAL CONTRACEPTIVES IN METABOLIC SYNDROME

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 口服避孕药(OCS)是目前应用最广泛的可逆节育方法。然而，广泛使用的低剂量OCS(50克乙炔雌二醇)的长期心血管安全性仍存在争议。尽管心血管事件在年轻女性中很少发生，无论她们是否使用OCS，但使用OCS的人如果有传统的心血管危险因素，如吸烟、糖尿病或高胆固醇血症，则心肌梗死和缺血性中风的风险会增加。然而，具有新的心血管危险因素的OC使用者的心血管事件的风险尚未被调查。代谢综合征就是这样一个新出现的心血管风险因素。最近，代谢综合征与心血管疾病的风险有关。该综合征是风险因素在单个个体中的聚集，其潜在原因可能是胰岛素抵抗。 这位研究人员的长期目标是了解预防和治疗女性心血管疾病的最佳方法。这一特殊应用的目的是获得有关代谢综合征对服用口服避孕药的女性心血管风险的影响程度的试点数据。 我们假设代谢综合征预示OC使用者的心血管风险更高。这项研究的结果将阐明服用口服避孕药的女性心血管事件的危险因素，并将作为NIH提案的试点数据。一旦了解了OC使用者的心血管危险因素，临床医生就可以在知情的情况下对患者的避孕选择做出更好的决定。 这项拟议的研究是创新的，因为代谢综合征对OC使用者心血管危险因素的影响以前还没有研究过。在这些研究完成后，我们的预期是OCS的使用会恶化患有代谢综合征的女性的胰岛素抵抗、高凝状态和炎症标志物。总而言之，这些研究的结果将澄清合适的业主立案法团人选，从而使适当使用危害最小的业主立案法团成为可能。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Oral contraceptives (OCs) are the most widely used method of reversible birth control. However, the long-term cardiovascular safety of the widely used low-dose OCs (ethinyl-estradiol < 50 g) is still debated. Although cardiovascular events are rare in young women whether they use OCs or not, the risks of myocardial infarction and ischemic stroke are increased among users of OCs who have conventional cardiovascular risk factors such as use of tobacco, diabetes or hypercholesterolemia. However, the risk of cardiovascular events in OC users with emerging cardiovascular risk factors have not been investigated. One such emerging cardiovascular risk factor is the metabolic syndrome. Recently, the metabolic syndrome has been linked with the risk of cardiovascular disease. The syndrome is a clustering of risk factors in a single individual, and its underlying cause may be insulin resistance. The investigator's long-term goal is to understand the best way to prevent and treat cardiovascular disease in women. The objective of this particular application is to obtain pilot data on the extent to which the metabolic syndrome affects cardiovascular risks in women taking OCs. We hypothesize that the metabolic syndrome predicts higher cardiovascular risks in OC users. Results of this study will clarify the risk factors for cardiovascular events in women taking OCs, and will serve as pilot data for an NIH proposal. Once the cardiovascular risk factors of OC users are understood, clinicians can make better informed decisions about contraceptive choices in their patients. The proposed research is innovative, because the effects of the metabolic syndrome on cardiovascular risk factors in OC users have not been previously studied. At the completion of these studies, our expectation is that use of OCs worsens insulin resistance, hypercoagulability and inflammatory markers in women with the metabolic syndrome. Collectively, the results of these studies will clarify the proper candidates for OCs, so that the appropriate use of OCs with the least harm will be possible.